Your browser doesn't support javascript.
Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept.
Anastasiou, Georgia; Hatziagelaki, Erifili; Liberopoulos, Evangelos.
  • Anastasiou G; Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece; and.
  • Hatziagelaki E; Second Department of Internal Medicine, Research Institute and Diabetes Center, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Liberopoulos E; Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece; and.
J Cardiovasc Pharmacol ; 78(1): e12-e19, 2021 07 01.
Article in English | MEDLINE | ID: covidwho-1232234
ABSTRACT
ABSTRACT Epidemiological studies indicate that diabetes is the second most common comorbidity in COVID-19 (coronavirus disease 2019). Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, exerts direct cardioprotective and nephroprotective effects. DARE-19 (Dapagliflozin in Respiratory Failure in Patients With COVID-19), an ongoing clinical trial, is designed to investigate the impact of dapagliflozin on COVID-19 progression. This article discusses the potential favorable impact of dapagliflozin on COVID-19 and its complications.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Benzhydryl Compounds / Diabetes Mellitus, Type 2 / Sodium-Glucose Transporter 2 Inhibitors / COVID-19 Drug Treatment / Glucosides Type of study: Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: J Cardiovasc Pharmacol Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Benzhydryl Compounds / Diabetes Mellitus, Type 2 / Sodium-Glucose Transporter 2 Inhibitors / COVID-19 Drug Treatment / Glucosides Type of study: Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: J Cardiovasc Pharmacol Year: 2021 Document Type: Article